Immunosuppression after perforating keratoplasty: Introduction to the topic;Immunsuppression nach Perforierender Keratoplastik

Ophthalmologe

Volumn 104, Issue 5, 2007, Pages 371-372

  Birnbaum, F ^a   Reis, A ^a   Reinhard, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CORNEA OPACITY; DRUG COMBINATION; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; PENETRATING KERATOPLASTY; POSTOPERATIVE COMPLICATION; PROGNOSIS;

CORNEAL OPACITY; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS;

EID: 34250217468     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-007-1515-z     Document Type: Article

References (9)

1. Bertelmann E, Reinhard T, Pleyer U (2003) Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society. Ophthalmologe 100: 1031-1035
2. Birnbaum F, Böhringer D, Sokolovska Y et al. (2005) Immunosuppression with cyclosporine a and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 79: 964-968
3. Birnbaum F, Reis A, Böhringer D et al. (2006) An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 81: 767-772
4. Hill JC (1995) Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye 9: 422-428
5. Pleyer U (2003) [Immunomodulation in penetrating keratoplasty. Current status and perspectives]. Ophthalmologe 100: 1036-1044
6. Reinhard T, Mayweg S, Sokolovska Y et al. (2005) Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study*. Transpl Int 18: 703-708
7. Reinhard T, Reis A, Böhringer D et al. (2001) Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 239: 367-372
8. Reinhard T, Sundmacher R, Godehardt E et al. (1997) Preventive systemic cyclosporin A after keratoplasty at increased riskfor immune reactions as the only elevated risk factor. Ophthalmologe 94: 496-500
9. Reis A, Reinhard T, Voiculescu A et al. (1999) Myco-phenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 83: 1268-1271